Abstract: Stromal Derived Factor-1 (SDF-1) is a small, naturally occurring, potent chemokine with inherent angiogenic, neurogenic, anti-apoptotic protein, which is also a potent stem cell chemoattractant, cardiovascular disease, and other metabolic disturbances. The present invention provides methods for treating erectile dysfunction in a male subject comprising administering to the major pelvic ganglion supplying the cavernous nerves subject compositions comprising SDF-1. SDF-1 promotes stem cell activation, to the major pelvic ganglion supplying the cavernous nerves, helps cell preservation, and prevents adverse penile remodeling. It can be administered as a protein or by gene therapy including but not limited to plasmid DNA, viral transduction, or nanoparticle delivery directly to the penis or to the neurovascular bundle or other pelvic nerve structures during the time of surgery, or before injury, or to treat existing erectile dysfunction.

Abstract: Stromal Derived Factor-1 (SDF-1) is a small, naturally occurring, potent chemokine with inherent angiogenic, neurogenic, anti-apoptotic protein, which is also a potent stem cell chemoattractant, cardiovascular disease, and other metabolic disturbances. The present invention provides methods for treating erectile dysfunction in a male subject comprising administering to the major pelvic ganglion supplying the cavernous nerves subject compositions comprising SDF-1. SDF-1 promotes stem cell activation, to the major pelvic ganglion supplying the cavernous nerves, helps cell preservation, and prevents adverse penile remodeling. It can be administered as a protein or by gene therapy including but not limited to plasmid DNA, viral transduction, or nanoparticle delivery directly to the penis or to the neurovascular bundle or other pelvic nerve structures during the time of surgery, or before injury, or to treat existing erectile dysfunction.

Abstract: Hypotonic formulations and methods for delivering drugs to bladder, improving drug absorption and retention therein, and minimizing systemic toxicity, are provided. The formulation includes particles formed from the assembly or association between biocompatible polymers with and without low or high grafting density of polyethylene glycol (PEG) and a wide range of drugs. A hypotonic medium or water allows the particles to penetrate and distribute within bladder tissue, where the particles are capable of dissolution to release drugs for absorption and retention. A reduced level of local and systemic toxicity and side effects of the formulation, compared to delivery of drugs in their free form, provides an effective and safe drug delivery platform for treating bladder or associated diseases or disorders.

Abstract: The present invention provides a tissue scaffold mold apparatus and methods for use of the mold apparatus to simply, rapidly and easily form molded tissue scaffolds from fibrous proteins such as collagen, and with other matrix components having complex 3-dimensional designs that can be seeded with stem cells for creating biologically and mechanically functional tissues/grafts. The inventive methods and apparatus allows for tissue engineering of hollow or concave and tubular organs and tissues, and will have immediate impact in a wide range of biomedical areas from tissue engineering, regeneration and reconstructive surgery.

Abstract: Compositions and methods of treating endothelial disorders, including: asthma, erectile dysfunction, pulmonary hypertension, cardiovascular disorders, and other disorders, using a synergistic combination of at least one arginase inhibitor and at least one phosphodiesterase (PDE1), (PDE2) and/or (PDE5) inhibitor are described.